|  |  |
| --- | --- |
| Address | Reg. & Corporate Office:: 41, Nurani, Bankalapara, Subid Bazar, Sylhet-3100 Factory : BSCIC Industrial Estate, Khadimnagar, Sylhet-3103,Tel:+88-082-722241,0821-728512,Fax:NIL,email: info@silcopharma.com; web: www. silcopharma..com |
| Nature of Business | Silco Pharmaceuticals Limited has engaged in manufacturing and marketing of pharmaceuticals finished product in the categories of Antibiotics, Analgesics, Anti Diabetics, Narcotics, Antipyretics, Anti Inflammatory drugs, Anti Ulcerants, Multi medicines which are sold in local market.  |
| Major Products | Silco Pharmaceuticals Limited has 99 medicines (Biological and Non-Biological). |
| Market for the products | Local Market  |
| BSEC’s Consent for IPO | February 07, 2019 |
| Issue Date of Prospectus | February 11, 2019 |
| Subscription Open | March 7, 2019 |
| Subscription Close | March 19, 2019 |
| Security Trading Code | SILCOPHL |
| Public Offer of Ordinary Shares | 30mn shares |
| Offer Price  | Tk. 10 each (at par) |
| Authorized Capital | Tk. 1,050.00mn |
| Pre-IPO Paid-up Capital | Tk. 643.70mn |
| IPO Size  | Tk. 300.00mn |
| Post IPO Paid-up Capital | Tk. 943.70mn |
| Min. size for IPO subscription (per lot) | 500 |
| Foreign Currency reqd. for NRB and Foreign Applicants (per Lot) | USD 60.10or GBP 46.61or EUR 53.36 |
| Use of IPO proceeds |

|  |  |
| --- | --- |
| Particulars | Amount (BDT) |
| Factory Building Construction | 144.66mn (48.22%) |
| Existing Machinery Modernization, QC Lab Equipment |  97.35mn (32.45%) |
| Delivery Van & Other Vehicles |  36.31mn (12.10%) |
| IPO Expenses |  21.68mn (07.23%) |
| Total | 300.00mn (100%) |

 |
| NAV Per Share  | Tk. 27.05 as on June 30, 2018  |
| Earning Per Share (EPS) | Tk. 1.64 (for the period ended June 30, 2018)  |
| Dividend History | NIL in the last five years |
| Issue Manager | EBL Investments, City Bank Capital and Citizen Securities & Investment Limited |
| Auditor | Ahmad & Akhtar |